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Letters to the Editors ajog.orgFetal fibronectin testing in threatened preterm labor:
time for more study!TO THE EDITORS: I am concerned that the recent
systematic review and meta-analysis by Berghella and
Saccone,1 as well as the accompanying editorial by Macones,2
may overstate the appropriate conclusions. While Berghella
and Saccone do acknowledge that “further study must be
undertaken to better understand whether and under what
circumstances the predictive characteristics of the fetal
ﬁbronectin [FFN] test can be translated into better clinical
management,” this is perhaps not made sufﬁciently clear in
either the abstract or the editorial.
Of the studies reviewed, only 3 used FFN as part of a strict
protocol. Of these, one is unpublished, a second is under-
powered, and the third in fact did show reduced admission
and length of stay.3 The remaining 4 studies left management
to physician discretion.
Obtaining an FFN and leaving management entirely to
physician discretion would be analogous to obtaining a
midtrimester cervical length on all women and leaving
management to physician discretion. Imagine the mix of
bed rest, cerclage, and tocolysis that might ensue.
All that we can currently conclude is that obtaining a fetal
ﬁbronectin outside a strict clinical protocol is of no beneﬁt.
Thus, I submit that the more appropriate conclusion should
be that further study of FFN within a strict clinical protocol,
possibly in conjunction with cervical sonography, is
warranted. Failure to continue such study might deprive us of
a tool that, appropriately used, might save many women from
needless interventions. -
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2017.03.026REPLYWe thank Dr Heyborne for his interest in our work. As he
says, we did state in our meta-analysis on women with
threatened preterm labor (PTL),1 that “further study must be
undertaken to better understand whether and under what
circumstances the predictive characteristics of the fetal
ﬁbronectin [FFN] test can be translated into better clinical
management.”
This is for several reasons, of which we want to highlight at
least two. First, as Dr Heyborne states, protocols were not
used in all randomized controlled studies (RCTs) included.
FFN is predictive of preterm birth (PTB) in women with PTL,
but we might not have studied the right interventions for
those with positive results.
Second, our meta-analysis might have been underpowered
to detect an effect. The incidence of spontaneous PTB <37
weeks was 20.7% in the FFN knowledge group and 29.2% in
the no FFN knowledge group, with a relative risk of 0.72 (so a
28% decrease in spontaneous PTB), but the 95% conﬁdence
intervals just crossed 1 (0.52e1.01).1 A bigger sample size,
which can be achieved by further and larger RCTs, might
certainly make FFN eventually associated with signiﬁcant
beneﬁts.
Unfortunately, until further studies are done, in 2017 so far
one cannot recommend FFN to be routinely done for women
with PTL. That is why neither the Society for Maternal-Fetal
Medicine2 nor the American College of Obstetricians and
Gynecologists3 recommend FFN use alone for women with
PTL. The use of transvaginal ultrasound (TVU) cervical
length (CL) in women with PTL has instead been better
supported by evidence from RCTs.4
The best evidence for use of FFN in women with PTL is
for those with TVU CL 20e29 mm when a positive FFN can
lead to more aggressive management with admission,
steroids, and possibly tocolysis, while a negative FFN can lead
to a discharge home.4,5 This is part of a PTL management
algorithm based mostly on TVU CL screening, as shown in
the Figure and suggested in the Society for Maternal-Fetal
Medicine PTB Toolkit, both on the website5 and on the app.6
In conclusions, we do agree with Dr Heyborne that “the
more appropriate conclusion should be that further study of
FIGURE
Suggested algorithm for the management of PTL in
women with cervix < 3cm dilated on initial exam
o Consider admission
o Consider corticosteroids for fetal maturity
o Consider tocolysis
Obtain FFN and Perform TVU CL 
CL < 20 mm CL 20 – 29 mm CL ≥ 30 mm
FFN pos FFN neg
Discharge 
home 
PTL, preterm labor; CTX, contractions; FFN, fetal fibronectin; TVU CL, transvaginal ultrasound
cervical length. Modified from3.
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2017.03.027REPLYI thank Dr Heyborne for his comments about my recent
editorial.1 I certainly agree with Dr Heyborne that additional
research is useful and needed in almost all areas of clinical
obstetrics. However, we need to use the available data to
make decisions today about how best to care for our
patients. This is where the recent meta-analyses of Berghella
and Saccone2 is so useful because it clearly demonstrates
that, based on data available today, the promise of fetal
ﬁbronectin in the assessment of women with threatened
preterm labor has not been realized, and therefore, this test
should not be used routinely in clinical care (outside a
research study).
I do disagree with Dr Heyborne’s assessment that
future research on fetal ﬁbronectin should be driven
primarily by a strict protocol that prescribes a speciﬁc
course of action based on the results of the test. That is
certainly a reasonable place to start. But in the end,
what we really care about is how real doctors use test re-
sults in real practice. It is this type of research that is
most generalizable and reﬂective of how a screening/
diagnostic test has an impact on clinical care and patient
outcomes. -
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